Project Grant R01AG089666
Award Date
8/1/24
Completion Date
4/30/29
Dollars Obligated
$2.3M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Boulder, CO 80309, USA
Similar Awards
This $2,365,042 Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) supports a comprehensive research study to evaluate the biological underpinnings of Alzheimer's disease and related dementias (ADRD) across the U.S. and India. The study aims to leverage harmonized data on neurodegenerative biomarkers, cognitive outcomes, and other markers to assess the interplay between biological factors, social determinants, and ADRD risk. Key...
This federal Project Grant award of $528,876.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) to Emory University will support a 5-year research study to investigate the genetic regulation of brain transcriptomics and proteomics associated with Alzheimer's disease and related dementias (AD/ADRD). The key objectives are to: Estimate genome-wide cis- and trans-acting quantitative trait loci (QTLs) for transcriptome-wide genes and proteome-wide proteins across multiple brain...
This federal Project Grant award from the National Institute on Aging's Aging Research Program (CFDA 93.866) provides $468,534 to the University of Southern California to examine alcohol consumption as a risk factor for Alzheimer's disease and related dementias (ADRD). The 2-year study aims to delineate the relationship between midlife alcohol use and late-life ADRD diagnosis and onset, explore interactions with the APOE gene, and leverage the twin design of the Swedish Twin Registry to better...
This $622,401 Project Grant award, funded by the National Institute on Aging (CFDA 93.866 - Aging Research), will support a multi-arm research project to elucidate the causal sequence of brain biomarker changes leading to Alzheimer's disease (AD) and identify modifiable lifestyle factors that could delay disease onset. The key research objectives include: Developing advanced deep learning models to predict amyloid load from readily available single-shell diffusion MRI data in symptomatic and...
This Cooperative Agreement award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support Boston University Medical Campus in conducting research to identify genetic and molecular mechanisms underlying the effects of the APOE gene on Alzheimer's disease (AD) risk and progression. The $810,698 award, which runs from September 15, 2024 to June 30, 2029, will enable the researchers to: Leverage large genome-wide association study (GWAS) datasets to discover new APOE...
This $6.18 million project grant from the National Institutes of Health's National Institute on Aging will fund the University of Texas at Austin to conduct the first large-scale genomic analysis of continuous rates of longitudinal aging-related cognitive change prior to dementia onset. Working with sub-awardees the University of Colorado and the University of Edinburgh, the researchers will identify genetic variants beyond APOE that confer risk for cognitive decline leading to eventual...
This Cooperative Agreement award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the University of North Carolina at Chapel Hill provides $763,225 to conduct research on gene-environment interactions related to Alzheimer's disease. The key objectives are to: Identify context-specific gene-environment interactions using an in vitro "GxE in a dish" model, where neural cells derived from 100 induced pluripotent stem cell donors are exposed to environmental factors...
This federal Project Grant award of $125,373 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to identify genetic associations between Alzheimer's disease (AD) and cardio-cerebrovascular risk factors (CVRFs) such as hypertension and diabetes. The overarching goal is to elucidate the interplay between genes, CVRFs, and AD risk, with the potential to reveal novel molecular targets for prevention and treatment strategies tailored to diverse racial/ethnic...
The National Institutes of Health's National Institute on Aging awarded a $7,432,562 project grant to the Regents of the University of California, San Francisco on September 15, 2022 under the Aging Research program (CFDA 93.866). The grant will support research to elucidate the roles of Alzheimer's disease risk genes and variants in gene expression and AD-related phenotypes through 2025. Specifically, the University of California, San Francisco will use CRISPR and single-cell RNA sequencing...
This $2,499,382 Cooperative Agreement award, funded by the National Institute on Aging's Aging Research program (CFDA 93.866), supports a multifaceted research project to investigate the role of chemical exposures in Alzheimer's disease (AD) and related dementias. The project leverages a large collaborative research infrastructure, including connections to 10 Alzheimer's Disease Research Centers, to expand coverage of the chemical exposome in blood and brain samples and link identified...